This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

CRESEMBA® in Mucormycosis: Adverse Events

In the VITAL trial, CRESEMBA had a favourable safety profile for fragile* difficult-to-treat patients with mucormycosis1.

†Reported in 10% or more of patients.
​​​​​​​*Fragile patients refers to patients with invasive fungal infections, who have severe/life-threatening underlying disease, may be immunocompromised, neutropenic, taking multiple therapeutic agents (including immunosuppressants and/or steroids or do not tolerate other antifungals

Explore more

Dosing

Access dosing information

References:
  1. ​​​​​​​Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
PP-CRB-GBR-1210. August 2021

Mucormycosis (Quick Links)

Safety Profile

 CRESEMBA safety information

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No